Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.41 |
| ▸ | PDE4A | P27815 | 13/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007232 | 1.00 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DMETAP2 | |
| SCHEMBL7767275 | 0.88 | PDE4A (0.40) | PDE4BPDE4APDE4CPDE4DMETAP2 | |
| SCHEMBL7763963 | 0.88 | PDE4A (0.40) | PDE4BPDE4APDE4CPDE4DMETAP2 | |
| SCHEMBL7995956 | 0.88 | MEN1 (0.41) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL7995948 | 0.88 | MEN1 (0.41) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL8004576 | 0.85 | PDE4B (0.45) | PDE4BPDE4DMEN1KMT2AROCK2 | |
| SCHEMBL8005152 | 0.85 | PDE4B (0.45) | PDE4BPDE4DMEN1KMT2AROCK2 | |
| SCHEMBL7765376 | 0.75 | EDNRA (0.41) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL7763145 | 0.75 | EDNRA (0.41) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL8647118 | 0.74 | PDE4A (0.45) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6025376-A | INHIBITORS OF TUMOR NECROSIS FACTOR, TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |